Is Wegovy Safe to Take? What the Evidence and Regulators Say

What the trial data and regulator said before approving it

The STEP 1 trial ran for 68 weeks and measured both efficacy and safety across nearly 2,000 participants. The profile that emerged was consistent across the programme: most adverse events were gastrointestinal, most were mild to moderate in severity, and most resolved without stopping treatment. On the strength of that evidence, the MHRA licensed Wegovy for weight management in the UK, and NICE subsequently recommended it for use within specialist weight management services for eligible adults. The medicine carries a Black Triangle (▼) designation, which means it is subject to additional monitoring — not because it is considered unusually dangerous, but because the MHRA collects extra post-market data on newer medicines as a standard safeguard. That monitoring feeds back into updated guidance over time, which is exactly how pharmacovigilance is supposed to work. Knowing this is worth something: it means the safety picture you read today is current, not fixed at the point of approval.

The broader question of how safe Wegovy is overall involves looking at both the trial data and real-world experience since launch, and the two broadly align.

The side effects most people actually experience

Gastrointestinal effects are by far the most reported. Nausea is the most frequent, affecting a sizeable proportion of people, particularly in the first few weeks or after a dose step up. Vomiting, loose stools, constipation, burping and indigestion are also common. Headache, fatigue and dizziness appear in a smaller number of people. Injection-site reactions (minor redness or discomfort) can occur but rarely persist. The NHS medicines page for semaglutide lists these in plain language and is worth reading before starting treatment.

Practically, the side effects are usually worst in the early weeks. Eating smaller portions, staying hydrated and avoiding rich or fatty foods around injection day helps many people. If you inject on a Sunday and you know the next week is busy, some people find Monday suits them better, that kind of small scheduling decision is worth raising during your consultation. The full side-effect profile of Wegovy covers each of these in more detail, including what tends to ease with time versus what warrants a call to your prescriber.

When to get medical help urgently

Most side effects are manageable. Some are not, and need prompt attention. Seek urgent medical care if you develop severe, persistent stomach pain that spreads to your back, with or without vomiting. This can be a sign of acute pancreatitis, a serious but infrequent complication. In January 2026 the MHRA published a Drug Safety Update on GLP-1 medicines specifically highlighting acute pancreatitis, describing it as a known but infrequent risk that clinicians and patients should be aware of. Do not wait to see whether it settles.

Other situations that need the same urgency: signs of a severe allergic reaction (swelling of the face, lips or throat, difficulty breathing), symptoms of significant dehydration after persistent vomiting or diarrhoea, or gallbladder pain (sharp pain in the upper right abdomen, sometimes with fever or jaundice). If you have any concern at all about a symptom, contact a prescriber or NHS 111 rather than dismissing it. Our support team is available seven days a week for aftercare queries, though anything urgent should go straight to a clinician or emergency services.

The question of whether the Wegovy injection specifically raises additional concerns beyond the medicine itself (needle length, injection technique, storage) is covered separately.

Who it is not suitable for, and what the prescriber checks

Wegovy is not recommended during pregnancy, while breastfeeding, or for anyone actively trying to conceive. It is not licensed for people under 18. A personal or family history of medullary thyroid carcinoma or a condition called MEN2 is a contraindication. Certain gastrointestinal conditions and a history of pancreatitis require careful prescriber discussion before treatment begins.

The safety of semaglutide also depends on what else you are taking. Women using oral contraceptive pills alongside tirzepatide (a different GLP-1 medicine) need to add a barrier method for a period, though the evidence for semaglutide specifically does not show the same degree of pill absorption reduction, still, it is worth raising with whoever prescribes your contraception. For a broader look at the safety profile of semaglutide across its uses, that page covers the interaction picture more fully.

At nume, every prescription involves a same-day clinical review by a GPhC-registered Independent Prescriber who considers your full medical history, current medications and weight-related conditions. The prescriber makes the suitability call, not a questionnaire, not software. If you have questions about how long it is safe to take Wegovy, that is a common consideration your prescriber will discuss with you as part of the assessment. If you would like to understand more about the Wegovy treatment itself before starting a consultation, that is a reasonable place to begin. The FAQs page explains the process, and our clinical team oversees all dispensing decisions.